XtalPi Partners with UCB to Accelerate Next-Gen Biologic Development via AI-Powered XtalFold™ Platform

Blog details
2 min read
Share this:

XtalPi (HKEX: 2228.HK) announced today that its biologics discovery division Ailux Biologics has entered into a strategic licensing agreement with Belgium-based global biopharmaceutical leader UCB (Euronext: UCB). Under the agreement, UCB gains access to XTALPI’s proprietary XtalFold™ AI platform for macromolecular drug discovery and engineering.

Platform Capabilities
The XtalFold™ suite enables rapid, high-accuracy structural modeling critical to biologic development stages including: 
– Antigen design & epitope mapping 
– Affinity maturation strategies 
– pH-sensitive modification 
– Bispecific antibody engineering 

Validated through rigorous benchmarking, XtalFold™ demonstrates industry-leading performance in modeling complex interactions at antibody-antigen interfaces – a persistent challenge in monoclonal antibody development. 

“UCB exemplifies how computational approaches can drive differentiated therapeutics. We’re honored to empower their R&D with AI-driven structural insights that accelerate life-changing discoveries.” 
Dr. Jian Ma, CEO of XtalPi Inc.

“Following the Nobel Prize recognition for protein structure prediction, XtalFold™ represents industrialized deployment of this breakthrough. As a fully validated solution, it’s becoming the new standard across biologics development.” 
Daniel Lightwood, Head of Antibody Discovery at UCB

“After exhaustive comparative testing, we’re confident XtalFold™ will enhance our ability to rapidly identify high-quality antibody candidates, ultimately delivering novel therapies to patients faster.” 
Dr. Alexander Hillisch, Global Head of CADD at UCB

Your next success starts here

Recommended articles

XtalPi Invests in MIT-Led Foundry Bio, Harnessing Generative AI to Transform the Trillion-Dollar Anti-Aging Market
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations 
XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration
XtalPi Advances Global STEM Education Through AI-Powered Science Outreach

XtalPi Newsletter